KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Non-Current Deffered Revenue: 2009-2023

Historic Non-Current Deffered Revenue for Halozyme Therapeutics (HALO) over the last 13 years, with Sep 2023 value amounting to $2.3 million.

  • Halozyme Therapeutics' Non-Current Deffered Revenue fell 20.47% to $2.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was $2.3 million, marking a year-over-year decrease of 20.47%. This contributed to the annual value of $2.3 million for FY2022, which is 10.95% down from last year.
  • As of Q3 2023, Halozyme Therapeutics' Non-Current Deffered Revenue stood at $2.3 million, which was down 0.00% from $2.3 million recorded in Q2 2023.
  • Over the past 5 years, Halozyme Therapeutics' Non-Current Deffered Revenue peaked at $4.0 million during Q4 2020, and registered a low of $641,000 during Q3 2020.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $2.5 million (2021), whereas its average is $2.7 million.
  • In the last 5 years, Halozyme Therapeutics' Non-Current Deffered Revenue slumped by 75.10% in 2019 and then spiked by 294.70% in 2021.
  • Quarterly analysis of 5 years shows Halozyme Therapeutics' Non-Current Deffered Revenue stood at $1.2 million in 2019, then surged by 222.85% to $4.0 million in 2020, then plummeted by 37.16% to $2.5 million in 2021, then declined by 10.95% to $2.3 million in 2022, then decreased by 20.47% to $2.3 million in 2023.
  • Its last three reported values are $2.3 million in Q3 2023, $2.3 million for Q2 2023, and $2.3 million during Q1 2023.